BiondVax to Present Tomorrow at Joseph Gunner Pioneers 2016 Conference

NESS ZIONA, Israel, May 4, 2016 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will be attending the Joseph Gunnar Pioneers 2016 conference in New York City.

On Thursday, May 5, Dr. Babecoff will be presenting at 10:30am at Pioneers 2016, a conference presented by Joseph Gunner & Co, taking place at the New York Palace Hotel.

The BiondVax presentation that Dr. Babecoff will be using is downloadable from BiondVax's website: http://www.biondvax.com/investor-presentation. Those wishing to meet one-on-one with Dr. Babecoff are invited to contact BiondVax.

About BiondVax Pharmaceuticals Ltd 

BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded onNASDAQ: BVXV and TASE: BVXV. For more information, please visit http://www.biondvax.com.

Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements. 

For further information, please contact:  

Company Contact
Joshua Phillipson
Business Development Manager
+972-8-930-2529 x5105
[email protected]

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
[email protected]

SOURCE BiondVax Pharmaceuticals Ltd.